COST invites proposals for Actions contributing to the scientific, technological, economic, cultural or societal development of Europe. Proposals playing a precursor role for other European programmes and/or initiated by early-stage researchers are especially welcome!
Proposers are invited to locate their proposal in one of the nine scientific Domains.
Interdisciplinary proposals not fitting readily into a single Domain are also welcome under the form of Trans-Domain Proposals (TDPs). To find out more about the intended coverage of each of the 9 scientific Domains, please visit the COST website.
All proposals are assessed in two stages. Preliminary Proposals, consisting of a brief overview and an impact description (maximum 1500 words/3 pages), are checked for eligibility first and, when eligible, assessed by the relevant Domain Committee against the published criteria. The top ranked Preliminary Proposals are then invited to submit a Full Proposal which is peer reviewed according to the published assessment criteria. The time between the collection date and the proposal for approval of the best Full Proposals by the COST CSO is approximately 6 months. COST - European COoperation in Science and Technology - brings together researchers and experts in different countries by setting up networks (Actions) centred on nationally funded research projects, which are of interest to at least five COST countries. COST financially supports activities such as meetings, conferences, short-term scientific exchanges and outreach activities in the range of EUR 100 000 per annum for normally 4 years. COST therefore does not fund research itself.
Full information on the open call is available on http://www.cost.esf.org/opencall which also gives access to the online submission template.
Sietske Zeinstra | COST Office
How Humans and Machines Navigate Complex Situations
19.11.2018 | Max-Planck-Institut für Bildungsforschung
A gene activated in infant and young brains determines learning capacity in adulthood
13.11.2018 | Universitätsklinikum Hamburg-Eppendorf
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.
Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
12.12.2018 | Health and Medicine
12.12.2018 | Physics and Astronomy
12.12.2018 | Health and Medicine